共 50 条
- [41] The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology LANCET RHEUMATOLOGY, 2021, 3 (04): : 306 - 312
- [45] Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S205 - S205
- [46] A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs PharmacoEconomics, 2001, 19 : 715 - 728
- [49] Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation HEALTH TECHNOLOGY ASSESSMENT, 2016, 20 (35) : 1 - +